{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Talazoparib in Advanced Breast Cancer With a Germline BRCA Mutation

Description

Method of Participation in the Learning Process/Evaluation Method

Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form.

Getting the Most out of the Activity

As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed.

While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.

Purpose of Activity

To provide information on the results of the EMBRACA Phase 3 study evaluating the use of talazoparib in advanced breast cancer patients with a germline BRCA mutation.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Summarize the purpose and design of the EMBRACA phase 3 evaluation of talazoparib in advanced breast cancer patients with a germline BRCA mutation.
  2. Outline the findings and implications of this study.
Price: $10.00

Credits:

  • ACCME 1.0 CME

Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Professions: Physician
Test Code: OT0219
Published: February 2019
Expires: 1/31/2021
Sources: Oncology Times
Passing Score: 7/10 (70%)
Authors: Richard Simoneaux